Comparative Pharmacology
Head-to-head clinical analysis: AMNESTEEM versus SOTRET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMNESTEEM versus SOTRET.
AMNESTEEM vs SOTRET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
Binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription to reduce sebum production, normalize follicular keratinization, and inhibit Propionibacterium acnes growth.
0.5-1.0 mg/kg/day orally in 2 divided doses
Oral isotretinoin 0.5-1 mg/kg/day divided twice daily for 15-20 weeks.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Clinical Note
moderateIsotretinoin + Estrone sulfate
"The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Estramustine
"The therapeutic efficacy of Estramustine can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Dienogest
"The therapeutic efficacy of Dienogest can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Medroxyprogesterone acetate
Terminal elimination half-life: 18-20 hours in adults; steady-state achieved after 5-7 days of dosing.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Primarily hepatic metabolism with renal excretion of metabolites (approximately 60-80% in urine) and fecal elimination (15-30%).
Category C
Category C
Retinoid
Retinoid
"The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin."